Abbott Laboratories Q1 1995 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1995. Abbott Laboratories is an Illinois corporation engaged in the pharmaceutical, nutritional, hospital, and laboratory products sectors. As of April 30, 1995, the company had approximately 798 million common shares outstanding.
Key Financial Metrics
| Metric | Q1 1995 | Q1 1994 |
|---|---|---|
| Net Sales | $2,524.4 million | $2,215.2 million |
| Net Earnings | $417.3 million | $366.2 million |
| Earnings Per Share (EPS) | $0.52 | $0.45 |
| Gross Profit Margin | 56.9% | 56.5% |
| Operating Earnings | $589.5 million | $527.0 million |
| Net Cash from Operating Activities | $508.3 million | $546.8 million |
| Cash and Cash Equivalents (End of Period) | $184.2 million | $171.1 million |
| Short-term Borrowings | $883.5 million | $772.5 million |
| Long-Term Debt | $285.5 million | $287.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 14.0% year-over-year, driven by unit growth and a 4.9% favorable impact from the weaker U.S. dollar on international sales.
- Profitability: Net earnings rose 13.9% and EPS increased 15.6%. Gross profit margin improved to 56.9% due to product mix shifts toward pharmaceuticals and productivity gains.
- Expense Trends: Selling, general, and administrative expenses increased 20.4%, attributed to new product marketing, charitable contributions, and litigation charges. R&D expenses rose to $247.2 million (9.8% of sales).
- Cash Flow: Net cash from operating activities decreased to $508.3 million from $546.8 million, primarily due to a $74.4 million increase in trade receivables.
- Capital Allocation: The company purchased and retired 5.36 million shares for $186 million. Dividends declared per share increased to $0.21 from $0.19.
Outlook, Risks, and Unusual Items
- Acquisition: In December 1994, a UK subsidiary acquired the nutritional business of Puleva Union Industrial y Agroganadera, S.A. for $106 million.
- Legal Proceedings: Significant litigation includes 23 pending antitrust suits regarding infant formula marketing and 107 suits regarding prescription drug pricing. Additionally, the Illinois Attorney General proposed a $750,000 civil penalty for alleged environmental violations at the North Chicago facility.
- Management Opinion: Management believes the ultimate disposition of pending legal and environmental matters will not have a material adverse effect on financial position or results of operations.
- Regulatory Risks: The company faces potential legislative changes regarding healthcare payment and delivery that could reduce prices or price increases for medical products.
- Liquidity: The company maintains AAA (S&P) and Aa1 (Moody's) bond ratings with $300 million in unused domestic lines of credit.
Investor Verification Checklist
- Verify the impact of the 107 pending antitrust suits on prescription drug pricing on future profitability.
- Monitor the resolution of the Illinois environmental enforcement action and potential cleanup costs.
- Assess the sustainability of the 14% sales growth given the 20.4% increase in SG&A expenses.
- Review the trend in trade receivables, which increased significantly ($74.4 million) compared to the prior year.
- Confirm the status of the $106 million Puleva acquisition integration and its contribution to the Nutritional segment.